Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC016520 | Panoply™ Human TRAF6 Knockdown Stable Cell Line | Inquiry |
| CSC-SC016520 | Panoply™ Human TRAF6 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT2553 | Human TRAF6 Knockout Cell Line-Hela | Inquiry |
| CSC-RT2686 | Human TRAF6 Knockout Cell Line-HEK293 | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD16824Z | Human TRAF6 adenoviral particles | Inquiry |
| LV28560L | human TRAF6 (NM_145803) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH433776 | shRNA set against Mouse TRAF6 (NM_009424.2) | Inquiry |
| SHH433780 | shRNA set against Rat TRAF6 (NM_001107754.2) | Inquiry |
| SHW009791 | shRNA set against Danio rerio TRAF6 (NM_001044752) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFR007395 | Rat Traf6 cDNA Clone(NM_001107754.2) | Inquiry |
| MiUTR1M-12081 | TRAF6 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-04905 | TRAF6 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-04906 | TRAF6 miRNA 3'UTR clone | Inquiry |
| CDCB171266 | Danio rerio TRAF6 ORF Clone (NM_001044752) | Inquiry |
| CDCB191795 | Rabbit TRAF6 ORF clone (XM_002709054.2) | Inquiry |
| CDCH094534 | Mouse Traf6 ORF clone (NM_009424.2) | Inquiry |
| CDCR374300 | Rat Traf6 ORF Clone(NM_001107754.2) | Inquiry |
| CDCS411882 | Human TRAF6 ORF Clone (BC031052) | Inquiry |
Tumor necrosis factor (TNF) receptor associated factor 6 (TRAF6), an E3 ubiquitin (Ub) ligase, is a signal transducer for the interleukin-1 (IL-1) receptor/Toll-like receptor (IL-1R/TLR) superfamily, including in response to cytokines, damage-associated molecular patterns, and pattern-associated molecular patterns. TRAF6 functions as an important signaling molecule to regulate a diverse array of physiological processes, including innate immunity, adaptive immunity, bone metabolism, and the development of skin, mammary glands, lymph nodes, and the central nervous system.
Among the members of TRAF family, TRAF6 has unique properties, which can not only mediate tumor necrosis factor receptor (TNFR) family signaling, but also affect signaling downstream of an unrelated receptor family, the IL-1R/TLR superfamily. TRAF6 is also an important E3 ubiquitin ligase, and cooperates with the dimeric ubiquitin-conjugating enzyme Ubc13/Uev1A to promote the unique Lys-63-linked poly-ubiquitin chains, instead of the conventional Lys-48-linked poly-ubiquitin chains that target proteins for degradation. It also interacts with various protein kinases including SRC, IRAK1 and PKCzeta, which provides a link between distinct signaling pathways. Apart from regulating the activity of IKK/NF-κB signaling, TRAF6 also modifies other proteins or signaling. TRAF6 was found to mediate activation of AKT, p38 and JNK. Linares et al. showed that TRAF6 was involved in mTOR activation through K63 polyubiquitination. Wei et al. demonstrated that TRAF6 negatively regulates the JAK-STAT signaling. TRAF6 expression is increased in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients, and its overexpression leads to hematopoietic defects in mouse genetic models. Besides, deletion of miR-146a and TIFAB, negative regulators of TRAF6 expression and function, are commonly observed in MDS and AML.
Some studies have shown that TRAF6 may play a role in cancer. A recent study identifies TRAF6 as a commonly amplified oncogene bridging NF-B and RAS in lung cancer. Overexpression of TRAF6 in primary mouse marrow cells led to a myelodysplastic syndrome that develops into a fatal acute myeloid leukemia. A positive correlation between TRAF6 in tumor margin cells and the histological grade and the mode of tumor invasion was found in laryngeal carcinoma. TRAF6 mediates oncogenesis of marginal zone B cell lymphoma of mucosa-associated lymphoid tissue. It promotes proliferation and regulates apoptosis of osteosarcoma, glioma, esophageal cancer and lung adenocarcinoma cells. TRAF6 promoted the migration and metastasis of esophageal squamous cell carcinoma (ESCC) cells by modulating Ras signaling. Overexpression of TRAF6 can promote the migration of ESCC cells and immortalized esophageal epithelial cells, but knock down the expression of TRAF6 can inhibit the migration and metastasis of ESCC cells in vivo and in vitro. TRAF6 mechanically binds Ras with its N-terminal and activated Ras signaling. Therefore, TRAF6 played an important role in the metastasis of ESCC cells and may be a promising therapeutic target.
In addition, TRAF6 expression was higher and more consistent in human cancer cell lines. And TRAF6 protein levels were found higher in myelodysplastic syndrome patients. It has been reported that amplification of the TRAF6 locus was a somatic and frequent event in a variety of human cancer types. TRAF6 is overexpressed in primary and metastatic melanoma tumors. Knockdown of TRAF6 significantly blocked melanoma cell invasion and metastasis in vivo and in vitro. Moreover, TRAF6 can directly interact with and ubiquitinate BSG resulting in MMP9 induction, which serves as a mechanism for melanoma invasion and metastasis. In addition, the expression of TRAF6 is upregulated in colon cancer, which is associated with tumor grades. TRAF6 promotes the proliferation of colon cancer cells through cyclin D1. These results indicate that TRAF6 plays an important role in the development of colon cancer. And it may become a potential target for colon cancer chemotherapy.
References: